Synthetic Process for RORγt Antagonist Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing compounds useful as RORγt antagonists are inefficient, with long sequences of chemical steps and low yields, which hinders their production as effective pharmaceutical intermediates for treating autoimmune diseases.
Innovation Solution
A streamlined process involving specific chemical reactions such as reacting Compound 1 with 4-fluorobenzenesulfinic acid, heptafluoroisopropyl iodide, reducing agents, trifluoroacetic anhydride, and chlorotrimethylsilane, along with L-(+)-tartaric acid, to produce Compounds of Formula (I), (II), and (III), improving yields and throughput.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods are used to prepare compounds useful as RORγt antagonists, then the compounds can be produced, but the process involves long sequences of chemical steps with low yields
Solution Approach 1:
The patent combines multiple chemical reaction steps into fewer integrated steps. Specifically, the process merges the formation of the sulfinic acid derivative, the introduction of the heptafluoroisopropyl group, and the subsequent transformations into a streamlined sequence that reduces the total number of discrete steps from the prior art to just 6-7 steps, thereby improving throughput and reducing cycle time
Solution Approach 2:
The patent performs preliminary functionalization of the starting material to create a more reactive intermediate that enables subsequent steps to proceed more efficiently. The use of 4-fluorobenzenesulfinic acid as a pre-prepared reagent allows for more efficient coupling reactions in later steps, reducing overall process time
2Productivity
If current methods are used to prepare compounds useful as RORγt antagonists, then the compounds can be produced, but the yields are low
Solution Approach 1:
The patent optimizes reaction parameters including temperature, solvent selection, and reagent stoichiometry to maximize yields at each step. The use of specific bases (Cs2CO3, K2CO3, NaHCO3) and controlled temperatures (0°C to room temperature) ensures high conversion efficiency and minimizes material loss throughout the synthesis sequence
Solution Approach 2:
The patent employs readily available, inexpensive reagents and solvents that can be easily handled and disposed of, such as common bases (carbonates, bicarbonates), standard organic solvents (THF, DMF, DCM), and commercial reducing agents (LiAlH4, NaBH4). This approach simplifies the process and improves overall yield by reducing complications from complex reagent handling
3Productivity
If the process is streamlined to reduce the number of chemical steps, then productivity improves, but manufacturing precision may be compromised
Solution Approach 1:
The patent uses carefully designed intermediate compounds that serve as stable, well-characterized species through which the synthesis passes. Each intermediate (compounds of formula I, II, and III) is structurally defined and can be isolated or carried through in high purity, ensuring that even though steps are reduced, the manufacturing precision and compound quality are maintained
Solution Approach 2:
The patent replaces multiple mechanical isolation and purification steps with more efficient chemical transformations that inherently produce high-purity products. The use of selective chemical reactions that proceed with high regio- and stereoselectivity eliminates the need for numerous purification steps, maintaining quality while improving throughput
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process enhances the production of high-quality compounds as active pharmaceutical ingredients by reducing the number of chemical steps, increasing yields, and ensuring high-quality output, making them suitable for use in treating autoimmune diseases.
Implementation Method 1
reacting Compound 1 with 4-fluorobenzenesulfinic acid in the presence of 1-methyl-2-pyrrolidinone and iodine to afford Compound 2
Implementation Method 2
reacting Compound 2 with heptafluoroisopropyl iodide in the presence of a base to afford Compound 3
Implementation Method 3
reacting Compound 3 with a reducing agent to afford Compound 4
Implementation Method 4
reacting Compound 4 with trifluoroacetic anhydride and sodium t-pentoxide in the presence of 2-methyltetrahydrofuran to afford Compound 5
Implementation Method 5
reacting Compound 7 with chlorotrimethylsilane, followed by L-(+)-tartaric acid to afford the Compound of Formula (I)
Data Source
AI summary
The invention generally relates to a process for preparing compounds, including Compound of Formula (I), useful as key intermediates in the preparation of compounds having RORγt antagonist properties.